Candriam SCA’s Larimar Therapeutics LRMR Stock Holding History

Candriam SCA’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-44,917	Closed	-$1.48M	–	828
2019 Q1	$1.48M	Hold	44,917	–	–	0.02%	557
2018 Q4	$2.67M	Buy	44,917 +3,584	+9%	+$354K	0.04%	401
2018 Q3	$5.8M	Buy	41,333 +27,583	+201%	+$3.35M	0.08%	288
2018 Q2	$1.69M	Buy	13,750 +5,833	+74%	+$495K	0.03%	521
2018 Q1	$708K	Buy	+7,917	New	+$671K	0.01%	635
2017 Q4	–	Sell	-10,833	Closed	-$458K	–	767
2017 Q3	$458K	Sell	10,833 -3,584	-25%	-$149K	0.01%	671
2017 Q2	$607K	Sell	14,417 -3,333	-19%	-$170K	0.01%	641
2017 Q1	$993K	Buy	17,750 +8,750	+97%	+$434K	0.02%	565
2016 Q4	$343K	Hold	9,000	–	–	0.01%	636
2016 Q3	$357K	Hold	9,000	–	–	0.01%	621
2016 Q2	$647K	Hold	9,000	–	–	0.02%	517
2016 Q1	$718K	Sell	9,000 -1,033	-10%	-$81.5K	0.02%	489
2015 Q4	$757K	Hold	10,033	–	–	0.02%	420
2015 Q3	$3.85M	Buy	10,033 +1,700	+20%	+$766K	0.09%	236
2015 Q2	$3.46M	Hold	8,333	–	–	0.07%	288
2015 Q1	$3.96M	Buy	+8,333	New	+$3.96M	0.08%	292

Other funds holding LRMR

AVA

Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Candriam SCA's LRMR Position: Q2 2019 in Review

Candriam SCA sold out of Larimar Therapeutics (LRMR) in Q2 2019, closing a stake of 44,917 shares — an estimated $1.48M sold.

Candriam SCA first reported a position in LRMR in Q1 2015 and held it in 16 quarters. The position peaked at $5.8M in Q3 2018. 71 funds tracked by Wall St. Rank hold LRMR as of Q2 2019.

Candriam SCA reported no remaining Larimar Therapeutics position as of Q2 2019 after selling out during the quarter.
Candriam SCA sold 44,917 Larimar Therapeutics shares in Q2 2019, an estimated $1.48M.
Candriam SCA first reported a position in Larimar Therapeutics in Q1 2015 and held it in 16 quarters.
Candriam SCA's Larimar Therapeutics position peaked at $5.8M in Q3 2018.
71 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2019.

Based on Candriam SCA's 13F filing for Q2 2019, filed 1 Aug 2019.